Physicochemical Characterization of Altebrel™, a Proposed Etanercept Biosimilar

BACKGROUND: Etanercept is prescribed for the rapid and effective treatment of chronic immune-mediated inflammatory disorders. Due to the expiration of etanercept patents and worldwide demand for comparable and more affordable substitutes, several biosimilars of etanercept have been approved in diffe...

Descripción completa

Detalles Bibliográficos
Autores principales: Fazel, Ramin, Mahboudi, Fereidoun, Seyedjafari, Ehsan, Sardari, Soroush, Vaziri, Behrouz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Institute of Genetic Engineering and Biotechnology 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357702/
https://www.ncbi.nlm.nih.gov/pubmed/32671128
http://dx.doi.org/10.30498/IJB.2019.99581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357702/
https://www.ncbi.nlm.nih.gov/pubmed/32671128
http://dx.doi.org/10.30498/IJB.2019.99581

Ejemplares similares